相关临床试验
42
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
22
52.4%
尚未招募
4
9.5%
招募中
16
38.1%
暂无批准数据
- Researchers at Hokkaido University developed e-MITO, a surface engineering approach that coats isolated mitochondria with PEG and cell-penetrating peptides to enhance stability and cellular uptake. - In laboratory experiments, CPP–PEG-engineered mitochondria were taken up more efficiently by cells than unmodified mitochondria and led to increased mitochondrial respiratory activity in recipient cells. - The modular design could enable mitochondria to be targeted to specific diseases or tissues, representing an early step toward using organelles as therapeutic tools. - The study, led by Professor Yuma Yamada, was published in Advanced Materials Interfaces and supported by JST FOREST Program and AMED.
- The global cytotoxicity assays market was valued at $17.1 billion in 2024 and is projected to reach $41.2 billion by 2034, growing at a CAGR of 9.2%. - North America held a dominant 39.9% market share in 2024, while Asia-Pacific is expected to record the fastest growth driven by expanding biotechnology investments. - Cytotoxicity assay-based kits led the product segment at 48.5% share, with nephrotoxicity applications accounting for 39.4% of the market by application in 2023. - Regulatory emphasis on reducing animal testing and adoption of 3D spheroid models, organ-on-chip platforms, and high-throughput screening are accelerating market innovation.
- Researchers report that disrupting de novo fatty acid biosynthesis rewires cellular lipid metabolism toward mTOR signaling, revealing a mechanistic link between lipid synthesis and growth control. - The study was supported by Kazusa DNA Research Institute and multiple Japanese funding agencies, including AMED-CREST and JST FOREST, underscoring its institutional and scientific significance. - Findings suggest that targeting fatty acid biosynthesis may offer a strategy to modulate mTOR-dependent pathways with potential therapeutic relevance. - The work is published under a Creative Commons Attribution 4.0 International License, ensuring open access to the research community.
- A cross-sectional study of 2,044 older Japanese adults found that lower plasma vitamin C levels were associated with reduced gray matter volume and weaker connectivity within the brain's default mode network. - The findings, published in PLOS ONE, represent the first direct demonstration of an association between blood vitamin C levels and structural brain network connectivity. - Researchers emphasize the observational nature of the study, noting it cannot establish causation and that the observed associations were modest compared to established risk factors like hypertension. - Maintaining optimal vitamin C levels through diet may be a simple strategy to support brain health during aging, though further longitudinal research across diverse populations is needed.
- AvenCell Therapeutics has dosed the first patient in its Phase I QUADvance study with AVC-203, marking the world's first CRISPR-engineered allogeneic CAR-T therapy to simultaneously target CD19 and CD20 antigens. - The therapy incorporates four key innovations including dual antigen targeting, immune evasion through CRISPR engineering, improved T-cell fitness from healthy donors, and switchable targeting capabilities for future indication expansion. - The program is supported by a $40 million grant from Japan's AMED and received FDA IND clearance and EMA approval on first submission, enabling trial initiation across multiple sites in the US and Europe. - AVC-203 addresses critical limitations of current autologous CAR-T therapies by offering off-the-shelf availability, consistent product quality, and massively scalable manufacturing for patients with relapsed/refractory B-cell malignancies.
- EpiFrontier Therapeutics received up to $32 million in non-dilutive funding from Japan's AMED to advance EPF-001, a novel G9a inhibitor targeting sickle cell disease and beta thalassemia. - EPF-001 emerged from over a decade of research at RIKEN and Tokyo University, involving screening of 140,000 compounds to identify a highly specific G9a inhibitor that increases fetal hemoglobin expression. - The funding will support Phase 2 clinical development with trials planned primarily at overseas institutions, while patient enrollment in Japan will focus on severe beta thalassemia cases. - The compound has demonstrated significant advantages over standard treatments in preclinical studies in terms of both efficacy and safety, positioning it as a potentially transformative therapy.
- Celaid Therapeutics raised JPY 1.055 billion ($7.2 million) in Series B funding from venture capital firms and Japan's AMED to advance its lead hematopoietic stem cell therapy program. - The company's CLD-001 therapy targets severe pediatric non-malignant diseases including aplastic anemia, primary immunodeficiency, and sickle cell disease using expanded cord blood stem cells. - Funding will support GMP manufacturing and non-clinical studies as the company prepares for U.S. clinical trials, with pre-IND discussions with FDA progressing according to plan. - CLD-001 addresses critical unmet needs in pediatric stem cell transplantation by solving donor shortage issues and providing HLA-matched cells to improve patient outcomes.
- Japanese researchers have isolated 10 natural compounds called onnamides from Okinawan marine sponges, with two showing exceptional activity against Leishmania major parasites. - Onnamide A and 6,7-dihydro-onnamide A demonstrated superior potency and safety compared to current leishmaniasis treatments, while operating through distinct mechanisms that could overcome drug resistance. - The compounds showed strong selectivity for parasites over human cells and may enable shorter treatment durations at lower concentrations. - Research is advancing under Japan's AMED Drug Discovery Booster program, with efforts underway to develop sustainable production methods using symbiotic bacteria.
- Elix and LINC have commercialized the world's first AI drug discovery platform incorporating federated learning models trained on data from 16 pharmaceutical companies, addressing the critical data scarcity challenge in AI drug discovery. - The platform leverages over 1 million compounds and 10 million data points through the kMoL federated learning library, enabling collaborative AI model development while preserving confidential pharmaceutical data. - The initiative emerged from Japan's AMED DAIIA project and includes AI models for on/off-target prediction, ADMET prediction, and molecular generation, with several pharmaceutical companies already adopting the Elix Discovery™ platform. - The commercialization represents a significant milestone in pharmaceutical AI, positioning the platform to become the de-facto standard for AI drug discovery in Japan while contributing to enhanced drug development capabilities globally.
- AvenCell Japan has been awarded up to $40 million in non-dilutive funding from Japan's AMED to support worldwide development of AVC203, a dual-antigen allogeneic CAR-T therapy targeting CD19 and CD20 for B-cell lymphomas. - The company's proprietary allogeneic technology uses multiple gene editing steps to prevent immune rejection while maintaining donor T-cell fitness and potency, addressing key challenges that have limited previous allogeneic CAR-T approaches. - Early clinical data from AvenCell's AVC201 program in relapsed and refractory AML patients demonstrate robust cell expansion and persistence beyond the typical one-month rejection period where other allogeneic candidates have failed. - The funding will enable AvenCell to collaborate with Japanese key opinion leaders and stakeholders to advance what the company describes as a paradigm-shifting therapeutic for patients with high unmet medical needs in lymphomas and leukemias.
